JOHNSON & Johnson, the largest health-care company in the world, has confirmed it is to invest £31 million in a state-of-the-art plant at Ringaskiddy, Co Cork, where 300 new jobs will be created. In addition to the new manufacturing facility, the project includes expansion of an existing warehouse, laboratory and administration buildings, and expansion of the wastewater treatment plant to accommodate increased volumes. Ringaskiddy, Cork, Ireland. It also includes expansion of the existing warehouse, laboratory administration buildings, support infrastructure and utilities. Other facilities to be expanded will be a new steam supply from existing boilers, and new process and potable water supply lines from existing on-site systems. The facility…, Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…, Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here, “The facility can undertake fermentation and purification tasks and includes a process development centre.”, Evergreen Theragnostics’ Radiopharmaceutical Manufacturing Facility, New Jersey, Aphena Pharma’s Solid Dose Division Expansion, Cookeville, Tennessee, Fujifilm Diosynth Biotechnologies’ Advanced Therapies Innovation Centre, College Station, Texas, Targeting the tumour stroma: Phenomic AI launches with $6m seed financing, Breaking the taboo: disrupting the fertility sector, Why Bahrain is the ideal strategic hub for Healthtech, How medical-grade silicone can transform transdermal drug delivery, Tackling fibrosis: Galecto raises $64m in equity financing, Merck’s ADC Manufacturing Facility Expansion, Madison, Wisconsin, USA.
Repurposing approved compounds for COVID-19 can expedite regulatory review, but changing formulation, dosing, and administration route may add risks.

The pharmaceutical giant just announced the withdrawal from sale of its talc baby powder from supermarkets in the US and Canada.

Johnson & Johnson will invest more than $350 million at its plant in Ringaskiddy, Ireland, where it makes APIs for some of its biologics. It sells Simponi for treating rheumatoid arthritis.
Johnson & Johnson Family of Companies have more than 265 operating companies in more than 60 countries employing approximately 126,500 … Johnson & Johnson Family of Companies is the world’s most comprehensive and broadly based manufacturer of healthcare products, as well as a provider of related services for the consumer, pharmaceutical and medical devices and diagnostics markets. Enclose phrases in quotes. Established by Centocor Biologics (now Janssen), the facility has a total built-up area of 28,400m² on 40.1ha of land. The expansion was aimed to increase production capacity to meet patient demand. Aramark Cleanroom Services provides contamination control products for sterile and... ALM Systems manufactures and supplies instruments to measure and control... AqVida is a pharmaceutical company that focuses on the development,... Evergreen Theragnostics, a radiopharmaceutical contract development and manufacturing organisation (CDMO) based in New Jersey, US, is developing a state-of-the-art radiopharmaceutical…, Aphena Pharma Solutions announced the expansion of its Solid Dose Division in Cookeville, Tennessee, US in September 2020. But, of course, it is J&J’s $7 billion global seller, Remicade, which is its biggest seller for treating rheumatoid arthritis and Crohn’s disease.

The expanded facility is expected to produce 72 batches of monoclonal antibody product a year. It produces antibodies and therapeutic proteins derived from cell cultures of genetically modified microorganisms through a water-based process. He added: "Our impact on the local environment will be most evident in visual terms and we have challenged our design team with the task of preparing a visually-pleasing facility as well as one which meets our very exacting production requirements and local planning specifications.".

The warehouse expansion will increase material weighing, dispensing and storage capacity, and will add a designated waste material segregation and storage area.

The Ringaskiddy facility manufactures products used for the treatment of conditions, including rheumatoid arthritis, psoriasis and cancer.

Previously, Ringaskiddy has focused mainly on the pharmaceutical industry, and the new development is very much in line with the commitment given by IDA Ireland to the local community that new investments would be brought to Ringaskiddy," he said. The production process involves a cell culture stage and a purification stage. Don’t add new lines with custom serialization software. It was anticipated, he added that the plant would be in production by the third quarter of 1998. Janssen declined to say what specific products are manufactured at the plant, but its Stelara is approved for treating Crohn's disease and Velcade for treating multiple myeloma. exclude terms. The project is kicking off this month and is expected to take two years to complete. Subscribe to FiercePharma to get industry news and updates delivered to your inbox.

In fact, it has been so successful, that Pfizer last month sued J&J, calling the special deals anticompetitive.

Other upgrades will include expansion of the existing low-voltage power infrastructure, underground fire main around the new building footprints, and BioCork1 lighting and CCTV services. JOHNSON & Johnson, the largest health-care company in the world, has confirmed it is to invest £31 million in a state-of-the-art plant at Ringaskiddy, Co Cork, where 300 new jobs will be created. The facility employs approximately 555 personnel.